Sulfasalazine-induced angioimmunoblastic lymphadenopathy developing in a patient with juvenile chronic arthritis

Rheumatol Int. 2000 Dec;20(1):25-7. doi: 10.1007/s002960000056.

Abstract

We describe a patient with juvenile chronic arthritis who developed reactive angioimmunoblastic lymphadenopathy, induced by sulfasalazine. Development of angioimmunoblastic lymphadenopathy although rare, is a very serious side effect of sulfasalazine treatment, and patients treated with this drug should be watched carefully.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antirheumatic Agents / adverse effects*
  • Arthritis, Juvenile / complications*
  • Arthritis, Juvenile / drug therapy
  • Arthritis, Juvenile / pathology
  • Chloroquine / toxicity
  • Humans
  • Immunoblastic Lymphadenopathy / chemically induced*
  • Immunoblastic Lymphadenopathy / drug therapy
  • Immunoblastic Lymphadenopathy / pathology
  • Lymph Nodes / pathology
  • Male
  • Methotrexate / therapeutic use
  • Methylprednisolone / therapeutic use
  • Sulfasalazine / adverse effects*

Substances

  • Antirheumatic Agents
  • Sulfasalazine
  • Chloroquine
  • Methylprednisolone
  • Methotrexate